



AU9468213

**(12) PATENT ABRIDGMENT (11) Document No. AU-B-68213/94**  
**(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 699487**

- (54) Title  
**METHODS OF TREATING AND DETECTING CANCER USING VIRUSES**
- International Patent Classification(s)  
(51)<sup>3</sup> C12Q 001/70 A01N 063/00 A61K 037/66 A61K 039/12  
A61K 039/42
- (21) Application No. : 68213/94 (22) Application Date : 29.04.94
- (87) PCT Publication Number : WO94/25627
- (30) Priority Data
- (31) Number (32) Date (33) Country  
08/055519 30.04.93 US UNITED STATES OF AMERICA
- (43) Publication Date : 21.11.94
- (44) Publication Date of Accepted Application : 03.12.98
- (71) Applicant(s)  
ROBERT M. LORENCE; KIRK W. REICHARD
- (72) Inventor(s)  
ROBERT M. LORENCE; KIRK W REICHARD
- (74) Attorney or Agent  
SPRUSON & FERGUSON , GPO Box 3898, SYDNEY NSW 2001
- (56) Prior Art Documents  
CANCER VOL 40 NO.2 (AUG 1977) P 680-686  
CANCER VOL 52 NO 5 (SEP.1983) P.856-860  
J.SURGICAL RESEARCH VOL 52 (MAY 92) P 448-453
- (57) Claim

1. A method of treating cancer comprising administering to a mammal in need of such treatment, an amount of Newcastle disease virus effective for treating said cancer, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.

7. A method of treating cancer comprising administering to said mammal in need of such treatment Newcastle disease virus, which alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.

OPI DATE 21/11/94 APPLN. ID 68213/94  
AOJP DATE 05/01/95 PCT NUMBER PCT/US94/04732



AU9468213

IN.

(51) International Patent Classification <sup>5</sup> : <b>C12Q 1/70, A61K 39/42, 39/12, 37/66, A01N 63/00</b>		A1	(11) International Publication Number: <b>WO 94/25627</b> (43) International Publication Date: 10 November 1994 (10.11.94)
(21) International Application Number: PCT/US94/04732 (22) International Filing Date: 29 April 1994 (29.04.94) (30) Priority Data: 08/055,519 30 April 1993 (30.04.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/055,519 (CIP) Filed on 30 April 1993 (30.04.93) (71)(72) Applicants and Inventors: LORENCE, Robert, M. [US/US]; 713 South Loomis, Chicago, IL 60607 (US). RECHARD, Kirk, W. [US/US]; 1416 West Farwell, Chicago, IL 60626 (US). (74) Agent: MARSCHANG, Diane, L.; William, Brinks, Hofer, Gilson & Lione, NBC Tower, Suite 3600, 455 North Cityfront Plaza Drive, Chicago, IL 60611-5599 (US).			(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published <i>With international search report.</i>
(54) Title: METHODS OF TREATING AND DETECTING CANCER USING VIRUSES			
(57) Abstract <p>The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal.</p>			

- 1 -

METHODS OF TREATING AND  
DETECTING CANCER USING VIRUSES

~~This invention was made with government~~  
5 support under Grant No. RR05477 awarded by the National  
Center for Research Resources. The government has  
~~certain rights in the invention.~~

FIELD OF THE INVENTION

10 The present invention relates generally to  
methods of treating and detecting cancer in mammals.  
More particularly, the invention relates to methods of  
treating and detecting cancer using certain viruses.

BACKGROUND OF THE INVENTION

1. Cancer Treatment

15 Despite recent advances in chemotherapy and  
radiation, cancer remains the second deadliest disease  
in the United States. There will be nearly two million  
new cancer cases diagnosed, and more than 525,000  
people are expected to die from cancer in 1993. The  
20 overall five-year survival approximates fifty percent  
for all patients, and the prognosis remains  
particularly poor for those with advanced solid tumors.

2. Effect of Viruses on Cancer

25 An association between exposure to various  
viruses and tumor regression has been the subject of  
several previous case reports. Most of the viruses  
described in those reports are pathogenic in humans,  
and include mumps and measles. The effect of other  
specific viruses on particular types of cancer cells  
30 has also been described. Smith et al., (1956) Cancer,  
2, 1211 (effect of APC virus on cervix carcinoma);

- 2 -

Holzaepfel et al., (1957) Cancer, 10, 577 (effect of APC3 virus on epithelial tumor); Taylor et al., (1970) J. Natl. Cancer Inst., 44, 515 (effect of bovine enterovirus-1 on Sarcoma-1); Shingu et al., (1991) J. General Virology, 72, 2031 (effect of bovine enterovirus, MZ-468, on F-647a leukemia cells); Suskind et al., (1957) PSEBM, 94, 309 (effect of Coxsackie B3 virus on HeLa tumor cells); Rukavishnikova et al., (1976) Acta Virol., 20, 387 (effect of influenza A strain on ascites tumor).

The earliest references described partial tumor regression in patients treated with live attenuated viral vaccine with the aim to vaccinate them against smallpox or rabies. See DePace, N.G. (1912) Ginecologia, 9, 82-88; Salmon, P. & Baix (1922) Compt. Rend. Soc. Biol., 86, 819-820. Partial regression of tumors and regression of leukemias have also been noted during naturally occurring measles infections. See Pasquinucci, G. (1971) Lancet, 1, 136; Gross, S. (1971) Lancet, 1, 397-398; Bluming, A.Z. and Ziegler, J.L. (1971) Lancet, 2, 105-106. In one study of 90 cancer patients intentionally infected with live mumps virus, partial tumor regression was noted in 79 cases. See Asada (1974) Cancer, 34, 1907-1928. Serious sequelae of infection with these human pathogens, however, is of major concern. Furthermore, the mechanism of any anti-cancer effect was never fully explored by the investigators. All of the effects noted upon exposure to those viruses were also temporary.

### 3. NDV Effect on Cancer

Newcastle Disease Virus ("NDV") is a member of the Paramyxovirus family. The natural hosts for NDV are chickens and other birds. NDV typically binds to certain molecules on the surface of animal host cells, fuses with the cell surface, and injects its genetic material into the host. Once inside, the viral genes

3

direct the host cell to make copies of the virus. These copies of NDV are then released to infect other cells, which in turn destroy the host cell. Unlike some viruses, NDV is not known to cause any serious human disease. Unlike many other kinds of viruses (e.g., herpes, hepatitis, HIV), the Paramyxoviruses do not interfere with the host cell genes, and are not known to be carcinogenic.

Temporary regression of tumors has been reported in a small number of patients exposed to NDV, all of whom eventually succumbed to their cancers. See, Csatory, L.K. (1971) *Lancet*, 2, 825. Csatory noted the regression of a gastrointestinal cancer in a chicken farmer during an epidemic of Newcastle disease in his chickens. In a similar anecdotal report, Cassel, W.A. and Garrett, R.E. (1965) *Cancer*, 18, 863-868, noted regression of primary cervical cancer, which had spread to the lymph nodes, in a patient following injection of NDV into the cervical tumor. Since the mechanism of the observed tumoricidal activity was thought to be immunologic, no work was carried out to address direct tumor cytotoxicity of the virus. Instead, efforts focused upon the immunomodulating effects of NDV. See, for example, Murray, D.R., Cassel, W.A., Torbin, A.H., Olkowski, Z.L., & Moore, M.E. (1977) *Cancer*, 40, 620; Cassel, W.A., Murray, D.R., & Phillips, H.S. (1983) *Cancer*, 52, 856; Bohle, W., Schlag, P., Liebrich, W., Hohenberger, P., Manasterski, M., Möller, P., and Schirmacher, V. (1990) *Cancer*, 66, 1517-1523.

#### Summary of the Invention

According to a first embodiment of the invention, there is provided a method of treating cancer comprising administering to a mammal in need of such treatment, an amount of Newcastle disease virus effective for treating said cancer, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.

According to a second embodiment of the invention, there is provided Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.

According to a third embodiment of the invention, there is provided the use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.

According to a fourth embodiment of the invention, there is provided a method of treating cancer comprising administering to said mammal in need of such treatment an amount of Newcastle disease virus effective for treating said cancer, wherein said cancer is selected from the group consisting of lung carcinoma, endometrial carcinoma, ovarian carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, synovial sarcoma,



3a

neuroblastoma, and glioblastoma, wherein said Newcastle disease virus is of moderate virulence.

According to a fifth embodiment of the invention, there is provided a method of treating cancer comprising administering to said mammal in need of such treatment  
5 Newcastle disease virus, which alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.

According to a sixth embodiment of the invention, there is provided Newcastle  
10 disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.

15 According to a seventh embodiment of the invention, there is provided the use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular,  
20 endoscopic, oral and topical administration.

According to an eighth embodiment of the invention, there is provided a method of treating cancer comprising administering to said mammal in need of such treatment  
Newcastle disease virus at a dose of at least  $4 \times 10^{10}$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of  
25 intravenous, intramuscular, intralesional, endoscopic, oral and topical.

According to a ninth embodiment of the invention, there is provided Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^{10}$  PFU per kg of body weight of said mammal, using a route of  
30 administration selected from the group consisting of intravenous, intramuscular, intralesional, endoscopic, oral and topical.

According to a tenth embodiment of the invention, there is provided the use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said  
35 cancer, at a dose of at least  $4 \times 10^{10}$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, intralesional, endoscopic, oral and topical.

According to an eleventh embodiment of the invention, there is provided a method of reducing the size of a tumor in a mammal having a tumor comprising administering to  
said mammal an amount of Newcastle disease virus effective to reduce the size of said



3b

tumor using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, wherein said Newcastle disease virus is of moderate virulence.

According to a twelfth embodiment of the invention, there is provided Newcastle disease virus when used in reducing the size of a tumor in a mammal having a tumor, using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, wherein said Newcastle disease virus is of moderate virulence.

According to a thirteenth embodiment of the invention, there is provided the use of Newcastle disease virus in the preparation of a medicament for use in reducing the size of a tumor in a mammal having a tumor, using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, wherein said Newcastle disease virus is of moderate virulence.

According to a fourteenth embodiment of the invention, there is provided a method of treating cancer in a mammal having cancer comprising administering an effective amount of:

- i) Newcastle disease virus, which is of moderate virulence, and which alone is cytolytic for said cancer and
- ii) and an agent selected from the group consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent.

According to a fifteenth embodiment of the invention, there is provided Newcastle disease virus, which is of moderate virulence, and which alone is cytolytic for said cancer, and an agent selected from the group consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent, when used in treating cancer in a mammal having cancer.

According to a sixteenth embodiment of the invention, there is provided the use of Newcastle disease virus, which is of moderate virulence, and which alone is cytolytic for said cancer, and an agent selected from the group consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent, in the preparation of a medicament for use in treating cancer in a mammal having cancer.

According to a seventeenth embodiment of the invention, there is provided a method of treating a human cancer comprising administering to a human in need of such treatment an amount of Newcastle disease virus effective for treating said cancer, which alone is cytolytic for said cancer, using a route of administration selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.

According to an eighteenth embodiment of the invention, there is provided Newcastle disease virus when used in treating a human cancer in a human in need of such treatment, wherein said virus alone is cytolytic for said cancer, using a route of administration selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.



3c

According to a nineteenth embodiment of the invention, there is provided the use of Newcastle disease virus in the preparation of medicament for use in treating a human cancer in a human in need of such treatment, wherein said virus alone is cytolytic for said cancer, and wherein said medicament is administered using a route selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.

The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus in a pharmaceutically-acceptable carrier. In one embodiment, the





- 4 -

virus is a Paramyxovirus. In a preferred embodiment, the virus is Newcastle Disease Virus.

5 The invention also provides a method of treating cancer in a mammal comprising administering to the mammal Paramyxovirus in combination with another agent, both being administered in amounts sufficient so that the combination is effective against the cancer.

10 The invention further provides methods of detecting cancer cells in a mammal. In one embodiment, Newcastle Disease Virus is employed as an imaging agent. To do so, labeled Newcastle Disease Virus may be administered and detected in the mammal. Alternatively, a labeled component that binds to Newcastle Disease Virus may be administered, and  
15 detected in the mammal. In another embodiment, Newcastle Disease Virus is administered to the mammal, and subsequently measured. The quantity of the virus measured in the body fluid or tissue of the mammal is an indication of the presence of cancer cells.

20 The invention further provides the use of Newcastle Disease Virus for the manufacture of a medicament for the treatment of cancer. Also, the invention provides the use of Newcastle Disease Virus for the manufacture of a diagnostic composition for  
25 detecting cancer cells.

The invention further provides an article of manufacture and kit containing materials useful for treating and detecting cancer. The article of manufacture comprises a container, a label on the  
30 container, and a composition contained within the container, the composition being effective for treating and detecting cancer, and the label on the container indicating that the composition can be used for treating and detecting cancer. The active agent in the  
35 composition comprises Newcastle Disease Virus. The kit comprises the container holding the composition effective for treating and detecting cancer, as well as

- 5 -

other compositions, such as buffers, diluents, and syringes.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5        Figure 1 illustrates the regression of IMR-32 human neuroblastoma xenografts in athymic mice following intra-tumor injection with live NDV (strain 73-T).

10       Figure 2 shows regression of HT-1080 human fibrosarcoma xenografts in athymic mice following intra-tumor injection with live NDV (strain 73-T).

Figure 3 shows regression of NCI-H460 human large cell lung carcinoma xenografts in athymic mice following intra-tumor injection with live NDV (strain 73-T).

15       Figure 4 shows regression of IMR-32 human neuroblastoma xenografts following systemic (intraperitoneal) injections of live NDV (strain 73-T).

20       Figure 5 illustrates the effectiveness of a strain (M, Mass MK107) of NDV of relatively moderate virulence with that of a strain of relatively high virulence (73-T) in causing tumor regression.

Figure 6 shows regression of U87MG human glioblastoma xenografts in athymic mice following intra-tumor injections with live NDV (strain 73-T).

25       Figure 7 shows growth inhibition of KB8-5-11 human cervical carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

30       Figure 8 shows regression of PC-3 human prostate carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

Figure 9 shows growth inhibition of HT29 human colon carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

35       Figure 10 shows growth inhibition of SK-BR-3 human breast carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

- 6 -

Figure 11 shows growth inhibition of SW620 human colon carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

Figure 12 shows growth inhibition of MM17387 human colon carcinoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

Figure 13 shows regression of TH15145 human synovial sarcoma in athymic mice following intra-tumor injections with live NDV (strain 73-T).

Figure 14 shows regression of a MEL330 human melanoma xenograft in athymic mice following intra-tumor injections with live NDV (strain 73-T).

#### DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

The present invention provides methods for treating mammalian cancer using certain viruses. In one embodiment of the invention, the virus is a Paramyxovirus. Paramyxoviruses useful in the practice of the present invention are preferably capable of specifically distinguishing mammalian cancer cells from normal mammalian cells. The Paramyxoviruses of the invention are also preferably cytolytic viruses. In an even more preferred embodiment of the invention, the cytolytic Paramyxovirus is a Newcastle Disease Virus ("NDV"). As used in the present application, the terms "virus," "Paramyxovirus," and "Newcastle Disease Virus" are employed in a broad sense and refer to both intact viruses and viral fragments, as well as genetically, physically or chemically modified viruses and viral fragments.

Paramyxoviruses, including various strains of NDV, both cytolytic and non-cytolytic, are publicly available, and may be obtained from vendors such as the American Type Culture Collection (ATCC), Rockville, MD.

The virus employed in the invention may be prepared by a variety of methods. For example, NDV may be prepared in 8 to 10 day old fertilized chicken eggs

- 7 -

(obtained from SPAFAS, Inc., Roanoke, IL). Methods of isolating the virus are known in the art and are described, for example, by Weiss, S. R. & Bratt, M. A. (1974) J. Virol, 13, 1220-1230. This method is further described in Example #1 below. Using this isolation method, NDV may be obtained which is about 90-95% pure.

Alternatively, the virus may be prepared in an in vitro cell culture. Preferably, the cell culture comprises mammalian cells, and more preferably, mammalian cancer cells. One advantage of using this method of preparing the virus is that it avoids problems associated with residual foreign proteins in the viral preparation. Mammalian cells contemplated by these methods include but are not limited to, human fetal fibroblasts and established cell lines such as HT1080 human fibrosarcoma (publicly available from ATCC) or the patient's own cancer cells. The cells may be anchorage-dependent or anchorage-independent.

Cell culture techniques that may be employed in the virus preparation are known in the art and may include use of stationary culture flasks with large surface areas or roller-type flasks. Preferably, the type of culture system selected can support relatively large numbers of cells.

Cell culture mediums that can be employed in the virus production are known to those skilled in the art. The medium typically includes a nutrient source, antibiotic(s) and albumin or a serum source that contains growth factor(s). It is within the skill in the art to select particular mediums and medium constituents suitable for the cells employed in the culture.

An example of a suitable culture medium for cultivating NDV in an in vitro cell culture is shown below in Table 1:

- 8 -

Reagent	Source	Amount
Opti-MEM	Gibco BRL Grand Island, NY	500 ml
Fetal Bovine Serum	Gibco BRL Grand Island, NY	50 ml
MEM Non-essential Amino Acids (100X), 10mM	Gibco BRL Grand Island, NY	5 ml
Antibiotic-Antimycotic (100X), contains 10,000 units penicillin, 10,000 $\mu$ g streptomycin and 25 $\mu$ g amphotericin B per ml	Gibco BRL Grand Island, NY	5 ml
Glutamine, (100X) 200mM	Gibco BRL Grand Island, NY	5 ml

Culture conditions typically include incubation at a desired temperature (such as 37°C), as well as selected concentrations of oxygen and carbon dioxide. The particular culture conditions selected can be determined in accordance with the cells employed in the culture, and determination of such conditions is within the skill in the art.

The cells are placed in the culture vessel and allowed to incubate and grow under the selected culture conditions. Preferably, anchorage-dependent cells are allowed to grow to confluence or peak growth. The time required for growth will vary depending upon the size of the initial cell inoculum added to the culture vessel and doubling time of the cell line being employed. Preferably, about  $3 \times 10^3$  to about  $3 \times 10^5$  cells are plated per  $\text{cm}^2$  and grown for one to five days. For virus inoculation of the cell culture, the medium is removed from the cells (for adherent cells, by aspiration of the culture medium; for cells grown in suspension, by centrifugation of the cell suspension and aspiration of the cell supernatant) and the virus (after reconstitution) is added to the cells in a minimal volume of medium or saline solution (such as Hank's Balanced Salt Solution, Gibco) to prevent

- 9 -

dehydration. Preferably, this volume ranges from about 10 to about 2500 microliter per cm<sup>2</sup> culture vessel surface area or 10<sup>5</sup> cells. The preferred dilution of virus inoculum ranges from about 0.001 to about 10 infectious units per cell, the optimal ratio depending on the particular virus and cell line. The virus is then grown from about 1 to 7 days, the length of time being primarily determined by the residual survival of the cell line. For NDV, the optimal time of harvest is 1 to 5 days after virus inoculation.

The virus can then be harvested by either removing the supernatant and replacing it with fresh medium or fresh medium with fresh cells at 12 to 48 hour intervals or freeze-thawing the cells to release virus in the supernatant. The supernatant can then be centrifuged and ultracentrifuged to recover the virus in relatively pure form. The purity of the viral preparation may be tested by protein determination and/or by electrophoresis. The virus can then be added to a pharmaceutically-acceptable carrier, described further below.

In accordance with a first method of treating cancer in a mammal, an effective amount of virus is administered to the mammal. The term "cancer" in the present invention is used in a broad sense and refers to the physiological condition in mammals that is usually characterized by unregulated cell growth. In one embodiment of the method, Paramyxovirus, preferably, NDV, is administered to the mammal. It is contemplated that such viruses may be used to treat a variety of cancers, including but not limited to lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma, and glioblastoma. The virus may be administered to the mammal at any time during

- 10 -

the course of malignant disease when cancer is detected to reduce primary tumor burden as well as metastatic spread. Alternatively, the virus may be administered as a prophylactic measure, prior to the onset or  
5 detection of cancer in the mammal. It is also contemplated that the virus may be administered to a mammal already treated for cancer if that cancer fails to completely respond or recurs. Preferably, if a tumor is operable, the virus is administered after  
10 the bulk of the tumor has been surgically removed.

Although not fully understood, it is believed that NDV has direct cytolytic activity on the cancer cells. It is also believed that NDV is capable of specifically differentiating cancer cells from normal,  
15 healthy cells. Results (not shown) have indicated that several oncogenes (H-ras, N-ras, and N-myc) which are known to confer malignant behavior to cancer cells, enhance the susceptibility of cells to killing by NDV. See, Lorence, R. M., Reichard, K. W., Cascino, C. J. et al. (1992) Proc. Am. Assoc. Cancer Res., 33, 398;  
20 Reichard, K. W., Lorence, R. M., Cascino, C. J., et al. (1992) Surg. Forum, 43, 603-606. In addition, it has been observed that treatment of cells with retinoic acid (vitamin A) also enhances lysis of cancer cells by  
25 NDV. Reichard, K. W., Lorence, R. M., Katubig, B. B., et al. (1993) J. Pediatr. Surg., 28, 1221.

Cytolytic activity by NDV is believed to be the result of direct binding of the virus to the cancer cell. A component of the cell surface molecule(s) allowing NDV binding to chicken cells has been  
30 identified. See, Paulson, J.C., Sadler, J.E. & Hill, R.C. (1979) J. Biol. Chem., 254, 2120-2124. The molecule appears to be relatively complex glycoprotein(s) and/or glycolipid molecule(s) on which  
35 sialic acid components are arranged in a particular configuration. It is the Applicants' present belief that the variations in sialic acid-containing

- 11 -

glycoproteins and/or glycolipids on the surface of cancer cells may mediate NDV's specificity and activity. For instance, sensitivity of cancer cells to NDV has been shown to be diminished by pre-treatment with neuraminidase which cleaves off the sialic acid residues. See, Reichard, K.W., Lorence, R.M., Katubig, B.B., et al. (1993) J. Pediatr. Surg., 28, 1221.

The virus may be administered to the mammal in a pharmaceutically-acceptable carrier.

Pharmaceutically-acceptable carriers are well known to persons skilled in the art. For instance, suitable carriers for administering the virus may include fluids such as water, saline, buffer, and cell culture medium. More preferably, a saline solution is used as the carrier. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of virus being administered.

The virus is preferably administered to the mammal by injection (e.g., intravenous, intralesional, intraperitoneal, subcutaneous, intramuscular or endoscopic). The virus can be administered either directly at the tumor site by local or regional injection, or systemically. Alternatively, the virus may be administered by routes including but not limited to intranasal, oral, rectal or topical application. Effective dosages and schedules for administering the virus may be determined empirically, and making such determinations is within the skill of the art.

Applicants have found local treatment doses in the range of about  $4 \times 10^8$  to about  $4 \times 10^{10}$  PFU of NDV per kilogram of body weight of the mammal to be particularly effective for treating tumors. For systemic treatment, Applicants believe that a range from about  $4 \times 10^{10}$  to about  $4 \times 10^{12}$  PFU per kilogram may be preferable in treating cancer. It is understood



- 12 -

by those skilled in the art that the dose of virus that must be administered will vary depending on, for example, the mammal which will receive the virus, the type of cancer, the extent of cancer cell growth or metastasis, the biological site or body compartment of the tumor(s), the strain of virus, the route of administration, and the identity of any other drugs or treatment being administered to the mammal, such as radiation, chemotherapy, or surgical treatment. It is also understood that it may be necessary to give more than one dose of the virus. The optimal interval between such multiple doses of virus can be determined empirically and is within the skill of the art. Administration of the virus should be continued until health has been restored to the mammal.

In accordance with another method of treating cancer in a mammal, an effective amount of virus is administered to the mammal in combination with another agent. In a preferred method, an effective amount of NDV is administered in combination with another agent. The virus may be administered to the mammal as described above. The other agent administered in combination with the virus may be a naturally-occurring or a synthetic substance, and preferably has anti-cancer activity, immune-enhancing activity, or virus-enhancing activity.

In one embodiment of the method, the agent is a cytotoxic or cytostatic agent. The cytotoxic or cytostatic agent may be a chemotherapeutic compound known in the art. Chemotherapeutic compounds contemplated by the present invention include, but are not limited to Thiotepa, Busulfan, Cyclophosphamide, Methotrexate, Cytarabine, Bleomycin, Cisplatin, Doxorubicin, Melphalan, Mercaptopurine, Vinblastine, 5-Fluorouracil, Taxol, and Retinoid Acid. Typically, cytotoxic or cytostatic agents function in destroying

- 13 -

cells and/or inhibiting their multiplication and are thus, useful in treating cancer.

5 In another embodiment of the method, the agent is an antibody. The antibody may be a naturally occurring antibody or an antibody modified biologically, chemically, physically, or genetically using methods which are within the skill of the art. Such antibodies may enhance the anti-cancer activity of the virus by binding to the tumor cell or to the virus  
10 after it is bound to the tumor cell.

In another embodiment of the method, the agent is an immune-enhancing agent such as an immunoadjuvant or cytokine. Immunoadjuvants and cytokines, also referred to as "biological response  
15 modifiers," are known in the art. Generally, such molecules are useful in stimulating or enhancing host defense mechanisms and are therefore useful in anti-cancer therapy. Examples of immunoadjuvants or cytokines that may be administered include, but are not  
20 limited to interferon(s), colony stimulating factor (CSF), tumor necrosis factor (TNF), growth factors, and interleukins such as IL-1, IL-2, and IL-6.

In another embodiment of the method, the agent is an immunosuppressive agent. Preferably, the  
25 immunosuppressive agent is a pharmaceutical compound known in the art. Immunosuppressive agents contemplated by the present invention include, but are not limited to Cyclosporin A, Azathiaprime, and Leflunomide and various corticosteroid preparations.  
30 Immunosuppressive agents are believed to function by blocking the immune response (cell-mediated, antibody-mediated, and cytokine-mediated) against viruses which may enhance the anti-cancer activity of the virus.

The agent is preferably administered in  
35 a pharmaceutically-acceptable carrier such as water, saline, or buffer. Modes of administration of the agent to the mammal include but are not limited to oral

- 14 -

administration or injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular). It is within the skill in the art to determine acceptable carriers and proper means of administering the agent.

5 The Paramyxovirus and the agent may be administered by the same means or by different means. For instance, the virus may be administered to the mammal by intravenous injection while the other agent is administered orally to the mammal.

10 The virus and agent may also be encapsulated in a liposome or other pharmaceutically-acceptable sac-like structure. Alternatively, the virus and the agent may be coupled by conjugation or linking techniques known in the art.

15 Effective dosages and schedules for administering the virus are described above. Effective dosages and schedules for administering the other agent in combination with the virus may be determined empirically, and making such determinations is within the skill of the art. Prior to administering the virus and the other agent, it is preferable to determine toxicity levels of all components so as to avoid deleterious effects. Depending on the agent administered, the virus and the agent may have additive or synergistic activity. For instance, administration of the virus may reduce the effective dosage required of the other agent. It will be understood by those persons skilled in the art that the dose of the other agent administered will vary, depending on, for

20 example, the mammal being treated, the type of cancer, the systemic location of the cancer, and the amount of virus being administered to the mammal. It is possible that multiple doses of the other agent must be administered in combination with the virus. The agent

25 may be administered at time intervals different from the virus administration. Intervals of the administration can be determined empirically, and such

30

35

- 15 -

determination is within the skill of the art.  
Administration of the virus and the agent should be continued until health has been restored to the mammal.

5       The invention also relates to a method of  
detecting cancer cells in a mammal using Paramyxovirus  
as an imaging agent. It is believed that such imaging  
may assist not only in diagnosis and detection, but may  
also guide further therapy such as surgery. In  
a preferred method, NDV is used as the imaging agent.  
10       To detect the cancer cells, the virus can be  
administered as described above. The virus then  
localizes to the cancer cell sites and binds to the  
cancer cells.

15       In one embodiment, labeled virus may be  
administered to the mammal. Labels useful in the  
method are well known in the art and include but are  
not limited to, enzymes, fluorophores, radioisotopes,  
and biotin-avidin. It is contemplated that  
radioisotopes such as Indium-111 having relatively  
20       short half lives will be preferred labels. The labels  
can then be readily detected by techniques known in the  
art.

25       Alternatively, a labeled component that binds  
to the virus may be administered to the mammal. For  
instance, enzyme-labeled or fluorescein-labeled anti-  
bodies having specific reactivity for virus epitopes  
may be administered to the mammal to identify and  
detect the presence and location of cancer cells to  
which the virus has bound.

30       The invention also provides a method of  
detecting cancer cells in the mammal comprising  
administering Paramyxovirus to the mammal, and then  
measuring the virus present in the body fluids or  
tissues of the mammal as an indication of cancer cell  
35       division or growth. The virus may be administered to  
the mammal as described above. After a pre-determined  
period of time, samples of body fluids or tissues may

- 16 -

be removed from the mammal and tested by standard techniques known in the art, including but not limited to, plaque assays, immunoassays of viral antigens, and polymerase chain reaction to detect portions of the viral genome. Using such techniques, the presence, if any, of the virus, viral antigens or viral nucleic acid can be detected and/or quantitated. In a preferred method, NDV levels are detected and quantified about one day to about four days after administration. Applicants believe that the quantitation of virus in the mammal, after administration of the virus, will correlate with tumor burden in the mammal and may be used to screen for occult tumors or cancers within the mammal, as well as to quantitate the amount of cancer within the mammal.

The invention further provides an article of manufacture and kit containing materials useful for treating and detecting cancer. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating and detecting cancer. The active agent in the composition comprises NDV. The label on the container indicates that the composition is used for treating and detecting cancer, and may also indicate directions for either in vivo or in vitro use, such as those described above.

The kit of the invention comprises the container described above and may further include other materials desirable from a commercial and user standpoint, including but not limited to buffers, diluents, filters, needles, syringes, cell culture medium and culture vessels.

- 17 -

EXAMPLES

Example #1: Treatment of human tumors in athymic mice with intralesional NDV.

5 Female athymic Balb-c mice were obtained from Life Sciences, Incorporated, St. Petersburg, FL and Charles River Laboratories, Wilmington, MA. They were housed in an isolated room in sterilized, filtered cages and given autoclaved-sterilized chow and water ad libitum. The care of these animals and the  
10 experimental protocols were conducted according to guidelines established by the Institutional Animal Care Committees, Cook County Hospital and Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL. Mice were obtained at approximately four weeks of age, and  
15 allowed to acclimate to their new environment for one week.

Tumor cell lines were obtained frozen from the American Type Culture Collection, Rockville, MD, and were derived from human tumors. The cell lines  
20 were maintained in Opti-MEM (Gibco-BRL, Grand Island, NY) containing 2.4 g/L sodium bicarbonate, 10% heat-inactivated fetal calf serum and 1/100 dilutions of the following 100X solutions: MEM non-essential amino acids (Gibco BRL catalogue number 320-1140AG); L-  
25 glutamine (Gibco BRL catalogue number 320-5030AG); and antibiotic-antifungal (Gibco BRL catalogue number 600-5240AG). The cells were placed into 225 mm<sup>2</sup> culture flasks and incubated at 37°C in 5% CO<sub>2</sub> to allow for adequate cell growth. The cells were then harvested by  
30 brief treatment with 0.25% trypsin (Gibco BRL, Grand Island, NY), washed in serum-free medium, and counted. The cells were then placed into serum-free medium at a concentration of 1x10<sup>7</sup> cells/0.1 milliliter in preparation for injection into the animals.

35 Under clean conditions, the tumor cells were then implanted into the subcutaneous space on the flank of the experimental animals by injecting 0.1 ml of

- 18 -

solution containing  $1 \times 10^7$  cells with a 25 gauge needle. The animals were then placed back in their cages, and the tumor cells were allowed to grow in the animals.

5 After approximately 10 days, tumors of 6.5 mm in diameter or greater were obtained in over 90% of animals. Animals bearing tumors of at least 6.5 mm in greatest diameter were randomly divided into three groups, marked, and the tumor dimensions carefully recorded by an independent observer.

10 NDV strain 73-T was obtained from William A. Cassel, Atlanta, Georgia and prepared as follows. Approximately 1000 plaque-forming units (PFU) of live virus particles were injected into 10-day old chick embryos (SPAFAS, Inc., Roanoke, IL). The eggs were  
15 incubated for 48 hours, during which time the virus replicated rapidly, killing the majority of the eggs. The allantoic fluid was then harvested from the embryos. Contaminating red cells, embryonic membranes and egg shell debris were removed from the allantoic  
20 fluid by two low speed centrifugations at  $7,520 \times g$  for 15 minutes each. The supernatant containing virus was then ultracentrifuged at  $50,000 \times g$  for 18 hours. The resulting virus pellet was then resuspended in Hank's Balanced Salt Solution (HBSS) (Gibco BRL, Grand Island,  
25 NY). A discontinuous sucrose gradient was prepared at concentrations of 20% and 55%, and the virus suspension was placed on the gradient and centrifuged for 1 hour at  $75,000 \times g$ . The purified NDV stock was harvested from the 20%-55% interface and stored at  $-80^\circ\text{C}$ .

30 Virus dose is usually expressed in plaque-forming units (PFU), or the number of infectious virus particles that are capable of replicating within and lysing cells. PFU's were measured in a plaque assay. Monolayers of HT 1080 human fibrosarcoma cells  
35 (American Type Culture Collection, Rockville, MD) or chick embryo cells (SPAFAS, Inc., Roanoke, IL) were formed on 50 mm plastic tissue culture plates in Opti-

- 19 -

MEM cell culture medium enriched with non-essential amino acids, glutamine, antibiotic-antimycotic, and 10% heat-inactivated fetal calf serum. Serial dilutions of virus in Hank's Balanced Salt Solution (HBSS) were added to the monolayers, and the virus particles were allowed to adsorb for 45 minutes at room temperature. If chick embryo cells were used, the monolayers were then sealed with a mixture of 0.9% Bacto-Agar (Difco, Detroit, MI) in culture medium. If HT 1080 cells were used, only cell medium was required. The monolayers were then incubated at 37°C in 5% CO<sub>2</sub> for 18 hours (for HT 1080 cells) or 2 days (for chicken embryo cells). All agar was removed and the cells were fixed with 100% methanol and stained with 0.2% crystal violet.

Clear areas on the monolayer, called plaques, represent the lytic effect of one infectious virus particle following replication within the cell monolayer. The number of plaques were counted, and the PFU/ml was calculated based upon the dilution factor for that plate.

The purified NDV stock was diluted in a saline solution (e.g., phosphate buffer saline, PBS) at a concentration of  $1 \times 10^7$  PFU/0.1 ml. The solution was divided into two groups, and one was treated by exposure to ultraviolet light to inactivate the viral genome. A third aliquot of saline alone was also prepared. The UV-killed virus and plain saline served as controls.

The three groups of animals were each treated by one of the three solutions described above, as follows. The tumor-bearing animal was thoroughly cleaned with alcohol, and the treatment solution was injected uniformly into the tumor using a 25 gauge needle and tuberculin syringe. The animals were then placed back into their respective cages again and observed. Every three days, the animals were examined by a blinded independent observer, who recorded tumor



- 20 -

size of each animal in each group and calculated tumor volume  $\{(\pi \times L \times H \times W)/6\}$ .

The results of these experiments are summarized in Figs. 1-3. The animals treated with live NDV experienced complete tumor regression within 30 days of treatment, while the animals treated with UV-inactivated virus or saline alone had unabated growth of their tumors.

In the case of neuroblastoma (IMR-32) (Fig. 1) complete tumor regression was observed in 18 out of 20 mice treated once with live NDV. Tumors in the other two mice regressed, but not completely, and required a second treatment 10 days later for complete regression. At day 23, one tumor that had completely disappeared began to regrow but a second virus treatment at day 23 led to a long-lasting complete regression. No tumor regression was observed in any of 8 mice treated with UV-killed NDV or in any of 19 mice treated with saline [ $P < 0.001$  (by Fisher's exact test) compared to the group treated with live NDV].

Fig. 2 shows the intralesional therapy of established HT 1080 human fibrosarcoma xenografts ( $\geq 0.6$  cm) in athymic mice using NDV ( $N=10$ ,  $10^7$  PFU) or saline control (PBS,  $N=9$ ). After a single treatment with live NDV, 8 out of 10 tumors completely regressed (the average sizes of these 8 tumors are plotted separately). The other two tumors maintained their sizes between days 2 and 24 (and their average sizes are plotted separately). Unabated tumor growth was noted in all nine mice treated with placebo [ $P < 0.005$  (by Fisher's exact test) for tumor regression compared to the group receiving NDV].

Fig. 3 shows the intralesional therapy of established NCI-H460 human lung large cell carcinoma xenografts in athymic mice using live NDV ( $N = 3$ ,  $10^7$  PFU) or saline control ( $N = 1$ ). Plotted separately are the tumor volumes in a logarithmic scale for each of

- 21 -

these four mice as a function of tumor after treatment. Complete tumor regression occurred in 2 out of 3 mice treated with live NDV. The tumor in the mouse treated with saline continued to grow unabated.

5           In summary, these examples show that one dose of NDV, given intralesionally to athymic mice, caused complete and permanent eradication of a wide variety of human tumors, which grew unabated in the control animals. Treatment of NDV with a short exposure to UV  
10           radiation, which damaged the genetic material so that the virus cannot replicate but can still bind, was no more effective than treatment with saline alone at causing tumor regression. The live NDV-treated animals were followed out for the remainder of their natural  
15           life, and very few tumor recurrences were observed in any of the animals. The recurrent tumors, however, completely regressed after a second local treatment of NDV. In addition, no untoward effects of virus treatment was noted in any of the animals.

20           Example #2: Treatment of human tumors in athymic mice using systemic NDV therapy.

          Athymic mice were injected with human tumor xenografts as described in Example #1. When tumors  
25           greater than 6 mm in diameter were achieved, the animals were divided into three groups. The NDV was prepared (see Example #1) in concentrations of  $1 \times 10^8$  PFU/0.3 ml or  $1 \times 10^9$  PFU/0.3 ml of saline. The control solution was an equal volume of saline alone.

          The abdomens of the animals were washed  
30           thoroughly with alcohol, and the NDV was injected intraperitoneally using a 25 gauge needle. One set of experimental mice ( $N = 3$ ) received a single injection of NDV at the higher dose ( $10^9$  PFU), while the other set of 4 mice received injections of  $10^8$  PFU three  
35           times per week. Control animals received injections of

- 22 -

saline. The animals were then observed and the tumor sizes were followed as described for Example #1.

5 The results are summarized in Fig. 4. Six out of 7 animals treated with intraperitoneal live NDV experienced complete regression of their tumors by day 52, while the animals treated with saline alone experienced unabated tumor growth. Complete tumor regression was noted in all mice treated only once with 10<sup>9</sup> PFU of NDV (--●--) and in 3 out of 4 mice treated 10 multiple times with 10<sup>8</sup> PFU of live NDV (--■--). Tumor volumes for the one mouse treated multiple times with 10<sup>8</sup> PFU of NDV which did not have complete tumor regression is plotted separately (--◆--). All the tumors treated with PBS (--o--) alone showed marked 15 tumor progression (P < 0.0025, Fisher's exact test).

The results demonstrate that NDV is effective at treating cancer when administered systemically. No untoward effects were noted in the animals from treatment with live NDV.

20 Example #3: Treatment of human tumors in athymic mice using attenuated strains of NDV.

NDV strain 73-T was obtained and prepared as described in Example #1. NDV strain M (Mass - MK107) is a strain less virulent than 73-T and was obtained 25 from Dr. Mark Peeples, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL. Strain M was replicated in a similar manner to that described in Example #1 for NDV strain 73-T.

Athymic animals were injected with human 30 HT1080 tumor cells subcutaneously as described above. They were allowed to develop tumors of at least 6.5 mm in diameter at which time they were randomly divided into three groups, and their tumor sizes were recorded.

The animals from one group were injected with 35 1.0 x 10<sup>8</sup> PFU of NDV strain 73-T in 0.1 ml saline intralesionally, as was described in Example #1. The

- 23 -

second group was injected with  $1.0 \times 10^8$  PFU of NDV strain M in 0.1 ml saline intralesionally. The last group was injected with 0.1 ml of saline alone. The animals were then observed and their tumor sizes were independently recorded every three days, as described in Example #1 above.

The results are shown in Fig. 5. As in Example #1, the tumors treated intralesionally with NDV strain 73-T disappeared completely. Two of the three tumors treated intralesionally with strain M similarly disappeared in less than three weeks. No regression occurred in control mice treated with saline.

Example #4: In vitro assays testing effect of NDV on human cancer cells.

NDV (strain 73-T, prepared as described in Example #1) was assayed with the human cancer cell lines listed below to determine sensitivity of each of the cell types to NDV.

KB-8-5-11 Cervical Carcinoma  
SW626 Ovarian Carcinoma  
SK-OV-3 Ovarian Carcinoma  
A172 Glioblastoma (brain cancer)  
HT1080 Sarcoma (fibrosarcoma)  
KHOS Sarcoma (osteosarcoma)  
IMR-32 Neuroblastoma  
SW620 Colon carcinoma  
HT29 Colon carcinoma  
NCI-460 Lung carcinoma (large cell)  
NCI-H510A Lung carcinoma (small cell)  
SK-MEL-3 Melanoma  
SK-MEL-28 Melanoma  
SCC25 Squamous cell carcinoma of head and neck  
MDMBA468 Breast carcinoma  
MDMBA157 Breast carcinoma  
SKBR3 Breast carcinoma  
PC3 Prostate carcinoma  
G104 Wilm's tumor

- 24 -

With the exception of the KB-8-5-11 Cervical Carcinoma and KHOS Sarcoma (osteosarcoma) cell lines, all the cell lines were obtained from ATCC, Rockville, Maryland. The KB-8-5-11 Cervical Carcinoma cell line was obtained from Dr. John Coon, Rush University, Chicago, Illinois, and the KHOS Sarcoma (osteosarcoma) cell line was obtained from Dr. Warren Knudson, Rush University, Chicago, Illinois. The cells and NDV were assayed according to the plaque assay described in Example #1, except that higher multiplicities of infection were used (ranging from 0.01 to 10). All of the assays were performed in parallel with control cultures treated with medium alone.

The results of the plaque assays showed that all of the cancer cell types were susceptible to cell killing by NDV. Cytolysis was observed 1 to 3 days after virus inoculation and in all cases was observed by phase contrast microscopy to consist of cell membrane disintegration and cell detachment.

Example #5: Treatment of human cancer cell tumors in athymic mice using intralesional NDV therapy.

In vivo experiments were conducted in accordance with the methods and procedures described in Example #1 with the following exceptions: (1) male athymic Balb-C mice obtained from Life Sciences were used as hosts for the PC3 prostate carcinoma cells; female mice were used as hosts for all other cancer cells tested; (2) tumor tissues identified as MM17387 colon carcinoma, TH14145 synovial sarcoma, and MEL 330 melanoma were obtained from surgical pathology specimens of cancer patients at Rush-Presbyterian-St. Luke's Medical Center and passed as tumor explants in athymic mice (See, Sharkey, et al., (1978) The Nude Mouse in Experimental and Clinical Research (Eds.: J. Fogh & B.P. Giovanella), Academic Press, New York, Volume 1, pp. 187-214) and treated with NDV or control saline at first or second passage. KB-8-5-11

- 25 -

cervical carcinoma cells were obtained from Dr. John Coon, Rush University, Chicago, Illinois. All other tumor cell lines described below and in Figs. 6-14 were obtained from ATCC, Rockville, Maryland.

5           Animals treated with live NDV experienced tumor regression or stabilization within 30 days of treatment, while the animals treated with UV-inactivated virus or saline alone had unabated growth of their tumors. The in vivo results showed that  
10       a single dose of NDV given intralesionally to athymic mice caused regression or growth inhibition of a wide variety of cancer cell tumors and that those cancer cell tumors grew unabated in control animals. No adverse side effects of virus treatment were noted in  
15       any of the animals. The results of the in vivo experiments are summarized in Figures 6-14.

          In the case of glioblastoma (U87MG) (Fig. 6), complete tumor regression was observed in 4 out of 4 mice treated once with live NDV. No tumor regression  
20       was observed in the one mouse treated with PBS.

          Fig. 7 shows the intralesional therapy of established KB8-5-11 cervical carcinoma xenografts using live NDV (N = 12, 10<sup>7</sup> PFU), UV-killed NDV (N = 12), or saline control (PBS, N = 12). After  
25       a single injection of live NDV, a marked growth inhibition was observed in all 12 mice. Unabated tumor growth was seen in all 12 mice treated with saline. A slight growth inhibition was seen in the mice treated with UV-killed virus.

30           Fig. 8 shows the regression of four NPC-3 human prostate carcinoma xenografts following intratumor injection with live NDV. The tumors in the mice treated with PBS continued to grow unabated.

          Figs. 9, 10 and 11 show the growth inhibition  
35       of HT29 colon carcinoma, SK-BR-3 breast carcinoma, and SW620 colon carcinoma xenografts following injection with live NDV compared to saline control.

- 26 -

5 Fig. 12 shows the growth inhibition of three MM17387 colon carcinoma xenografts (at second passage from the patient) following injection with live NDV compared to saline control. Three mice treated intra-tumorally with UV-killed NDV showed a lesser degree of growth inhibition.

10 Fig. 13 shows the intralesional therapy of established low-passage (passage #1 or 2) human TH14145 synovial sarcoma xenografts in athymic mice. Greater than 90% tumor regression was observed in six out of 9 mice treated with live NDV. No tumor regression was observed in any of the four mice treated with saline.

15 Fig. 14 shows the regression of a single MEL330 human melanoma xenograft in an athymic mouse following intratumor injection with NDV. Tumor progression was seen in the one mouse treated with saline.

The claims defining the invention are as follows:

1. A method of treating cancer comprising administering to a mammal in need of such treatment, an amount of Newcastle disease virus effective for treating said cancer, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.
2. Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.
3. Use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, and which alone is cytolytic for said cancer.
4. A method of treating cancer comprising administering to a mammal in need of such treatment an amount of Newcastle disease virus effective for treating said cancer, wherein said cancer is selected from the group consisting of lung carcinoma, endometrial carcinoma, ovarian carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, synovial sarcoma, neuroblastoma, and glioblastoma, and wherein said Newcastle disease virus is of moderate virulence.
5. The method, Newcastle disease virus or use of any of claims 1-4, wherein said Newcastle disease virus is strain MK107.
6. The method, Newcastle disease virus or use of any of claims 1-5, wherein said virus is administered by a route selected from the group consisting of intravenous, intraperitoneal, intramuscular, endoscopic, oral and topical administration.
7. A method of treating cancer comprising administering to said mammal in need of such treatment Newcastle disease virus, which alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.
8. Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.
9. Use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^8$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, endoscopic, oral and topical administration.
10. A method of treating cancer comprising administering to said mammal in need of such treatment Newcastle disease virus at a dose of at least  $4 \times 10^{10}$  PFU per kg of



body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, intralesional, endoscopic, oral and topical.

11. Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^{10}$  PFU per kg of body weight of said mammal, using a route of administration selected from the group consisting of intravenous, intramuscular, intralesional, endoscopic, oral and topical.

12. Use of Newcastle disease virus in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus alone is cytolytic for said cancer, at a dose of at least  $4 \times 10^{10}$  PFU per kg of body weight of said mammal using a route of administration selected from the group consisting of intravenous, intramuscular, intralesional, endoscopic, oral and topical.

13. The method, Newcastle disease virus or use of any of claims 7-12, wherein said administering step is made in multiple doses.

14. A method of reducing the size of a tumor in a mammal having a tumor comprising administering to said mammal an amount of Newcastle disease virus effective to reduce the size of said tumor using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, and wherein said Newcastle disease virus is of moderate virulence.

15. Newcastle disease virus when used in reducing the size of a tumor in a mammal having a tumor, using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, and wherein said Newcastle disease virus is of moderate virulence.

16. Use of Newcastle disease virus in the preparation of a medicament for use in reducing the size of a tumor in a mammal having a tumor, using a route of administration selected from the group consisting of intravenous, endoscopic, oral and topical administration, and wherein said Newcastle disease virus is of moderate virulence.

17. A method of treating cancer in a mammal having cancer comprising administering an effective amount of

i) Newcastle disease virus, which is of moderate virulence and which alone is cytolytic for said cancer, together with

ii) an agent selected from the group consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent.

18. Newcastle disease virus, which is of moderate virulence, and which alone is cytolytic for said cancer, together with an agent selected from the group consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent, when used in treating cancer in a mammal having cancer.

19. Use of Newcastle disease virus, which is of moderate virulence, and which alone is cytolytic for said cancer, together with an agent selected from the group



consisting of: a chemotherapeutic agent, a cytokine, and an immunosuppressive agent, in the preparation of a medicament for use in treating cancer in a mammal having cancer.

20. A method of treating a human cancer comprising administering to a human in need of such treatment an amount of Newcastle disease virus effective for treating said cancer, alone is cytolytic for said cancer, using a route of administration selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.

21. Newcastle disease virus when used in treating a human cancer in a human in need of such treatment, wherein said virus alone is cytolytic for said cancer, using a route of administration selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.

22. Use of Newcastle disease virus in the preparation of medicament for use in treating a human cancer in a human in need of such treatment, wherein said virus alone is cytolytic for said cancer, and wherein said medicament is administered using a route selected from intraperitoneal, endoscopic, oral and topical administration.

23. A method of treating cancer comprising administering to a mammal in need of such treatment, an amount of Newcastle disease virus effective for treating said cancer, wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.

24. Newcastle disease virus when used for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.

25. Use of Newcastle disease in the preparation of a medicament for treating cancer in a mammal in need of such treatment, wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.

26. A method of reducing the size of a tumor in a mammal having a tumor comprising administering to said mammal an amount of Newcastle disease virus effective to reduce the size of said tumor, and wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.

27. Newcastle disease virus when used in reducing the size of a tumor in a mammal having a tumor, and wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.



30

28. Use of Newcastle disease virus in the preparation of a medicament for use in reducing the size of a tumor, and in a mammal having a tumor wherein said Newcastle disease virus is of moderate virulence, substantially as hereinbefore described with reference to any one of the Examples.

Dated 21 October, 1998

Robert M. Lorence

Kirk W. Reichard


Patent Attorneys for the Applicant/Nominated Person

**SPRUSON & FERGUSON**




1/14

Fig. 1




2/14




3/14

Fig. 3




4/14

Fig. 4




5/14






6/14

Fig. 6




7/14

Fig. 7



8/14



9/14

Fig. 9






Fig. 10




11/14

Fig. 11




12/14

Fig. 12



13/14


Fig. 13





14/14

Fig. 14



## INTERNATIONAL SEARCH REPORT

Inte. .onal application No.  
PCT/US94/04732

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :C12Q 1/70; A61K 39/42, 39/12, 37/66; A01N 63/00  
US CL :435/5; 424/85.4, 86, 89, 93

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5; 424/85.4, 86, 89, 93

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

FILE BIOSIS PREVIEWS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CANCER, Volume 66, No. 7, issued 01 October 1990, Bohle et al., "Postoperative Active Specific Immunization in Colorectal Cancer Patients with Virus-Modified Autologous Tumor-Cell Vaccine", pages 1517-1523, see entire document.	1-10
X	CANCER, Volume 52, No. 5, issued 01 September 1983, Cassel et al., "A Phase II Study on the Postsurgical Management Stage II Malignant Melanoma With a Newcastle Disease Virus Oncolysate", pages 856-860, see entire document.	1-10
X	Cancer, Volume 40, No. 2, issued August 1977, Murray et al., "Viral Oncolysate in the Management of Malignant Melanoma", pages 680-686, see entire document.	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 JULY 1994

Date of mailing of the international search report

JUL 28 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20531

Facsimile No. (703) 305-3230

Authorized officer

LAURIE SCHEINER

Telephone No. (703) 308-0196